For example, a recent research work showed that therapeutic targeting of hepatic methylation-controlled J protein (MCJ) with nanoparticle- and GalNAc-formulated siRNA efficiently prevented liver lipid accumulation and fibrosis in multiple NASH mouse models [81]. This evidence concerns the gene DNAJC15 and metabolic dysfunction-associated steatohepatitis.